{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T23:41:38Z","timestamp":1781653298429,"version":"3.54.5"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008783","name":"University of Hawai'i at M\u0101noa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008783","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013429","name":"INBRE","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001159","name":"Hawaii Community Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001159","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ejpb.2021.04.026","type":"journal-article","created":{"date-parts":[[2021,5,7]],"date-time":"2021-05-07T03:43:51Z","timestamp":1620359031000},"page":"66-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Microemulsion-based gel for the transdermal delivery of rasagiline mesylate: In vitro and in vivo assessment for Parkinson\u2019s therapy"],"prefix":"10.1016","volume":"165","author":[{"given":"Pratikkumar","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhaval","family":"Kalaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit A.","family":"Date","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogeshvar","family":"Kalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Patravale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ejpb.2021.04.026_b0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/IJN.S13223","article-title":"Treatment of Parkinson's disease: nanostructured sol-gel silica-dopamine reservoirs for controlled drug release in the central nervous system","volume":"16","author":"Lopez","year":"2010","journal-title":"Int. J. Nanomed."},{"issue":"9","key":"10.1016\/j.ejpb.2021.04.026_b0010","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.clinthera.2007.09.021","article-title":"Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease","volume":"29","author":"Chen","year":"2007","journal-title":"Clin. Ther."},{"issue":"4","key":"10.1016\/j.ejpb.2021.04.026_b0015","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.amjopharm.2006.12.001","article-title":"Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease","volume":"4","author":"Guay","year":"2006","journal-title":"Am. J. Geriatr. Pharmacother."},{"key":"10.1016\/j.ejpb.2021.04.026_b0020","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2210-11-2","article-title":"Effects of rasagiline, its metabolite aminoindan and selegiline on glutamate receptor mediated signalling in the rat hippocampus slice in vitro","volume":"11","author":"Dimpfel","year":"2011","journal-title":"BMC Pharmacol."},{"key":"10.1016\/j.ejpb.2021.04.026_b0025","doi-asserted-by":"crossref","unstructured":"S. Abu-Raya, E. Blaugrund, V. Trembovler, et al., Rasagiline, a novel monoamine oxidase-B inhibitor with neuroprotective effects under ischemic conditions in PC12 cells. 50 (3\u20134) (2000) 285\u2013290.","DOI":"10.1002\/1098-2299(200007\/08)50:3\/4<285::AID-DDR11>3.0.CO;2-8"},{"issue":"3","key":"10.1016\/j.ejpb.2021.04.026_b0030","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.pneurobio.2010.06.008","article-title":"Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity","volume":"92","author":"Weinreb","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.ejpb.2021.04.026_b0035","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/978-3-7091-6499-0_29","article-title":"Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders","volume":"52","author":"Speiser","year":"1998","journal-title":"J. Neural Transm. Suppl."},{"issue":"4","key":"10.1016\/j.ejpb.2021.04.026_b0040","first-page":"413","article-title":"Role of rasagiline in treating Parkinson's disease: effect on disease progression","volume":"5","author":"Malaty","year":"2009","journal-title":"Ther. Clin. Risk Manag."},{"issue":"3","key":"10.1016\/j.ejpb.2021.04.026_b0045","first-page":"467","article-title":"Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy","volume":"3","author":"Lecht","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.ejpb.2021.04.026_b0050","unstructured":"T. Azilect, AZILECT; Product Monograph, Control no: 13427, Teva Pharmaceutical Industries Ltd., Israel, 2010."},{"issue":"1","key":"10.1016\/j.ejpb.2021.04.026_b0055","doi-asserted-by":"crossref","first-page":"109","DOI":"10.4155\/tde.10.16","article-title":"Challenges and opportunities in dermal\/transdermal delivery","volume":"1","author":"Paudel","year":"2010","journal-title":"Therap. Del."},{"issue":"10","key":"10.1016\/j.ejpb.2021.04.026_b0060","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s40265-017-0744-y","article-title":"Advanced analgesic drug delivery and nanobiotechnology","volume":"77","author":"Stoicea","year":"2017","journal-title":"Drugs."},{"issue":"s1","key":"10.1016\/j.ejpb.2021.04.026_b0065","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.3233\/JPD-181476","article-title":"Continuous drug delivery aiming continuous dopaminergic stimulation in Parkinson's disease","volume":"8","author":"van Wamelen","year":"2018","journal-title":"J. Parkinsons Dis."},{"issue":"3","key":"10.1016\/j.ejpb.2021.04.026_b0070","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/00002826-200005000-00002","article-title":"Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset","volume":"23","author":"Smith","year":"2000","journal-title":"Clin. Neuropharmacol."},{"issue":"8","key":"10.1016\/j.ejpb.2021.04.026_b0075","first-page":"613","article-title":"Extensive gastrointestinal metabolic conversion limits the oral bioavailability of the dopamine D2 agonist N-0923 in freely moving rats","volume":"47","author":"Swart","year":"1992","journal-title":"Pharmazie"},{"issue":"2 suppl 1","key":"10.1016\/j.ejpb.2021.04.026_b0080","first-page":"S3","article-title":"A novel dopamine agonist for the transdermal treatment of Parkinson\u2019s disease","volume":"65","author":"Jenner","year":"2005","journal-title":"Neurology."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2021.04.026_b0085","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijpharm.2011.10.039","article-title":"Oil based nanocarrier system for transdermal delivery of ropinirole: a mechanistic, pharmacokinetic and biochemical investigation","volume":"422","author":"Azeem","year":"2012","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.ejpb.2021.04.026_b0090","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1080\/17425255.2016.1194393","article-title":"Clinical pharmacology and efficacy of rotigotine (Neupro(R) patch) in the treatment of restless leg syndrome","volume":"12","author":"Ferini-Strambi","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"2","key":"10.1016\/j.ejpb.2021.04.026_b0095","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/1566523217666170510151540","article-title":"Recent advances in skin penetration enhancers for transdermal gene and drug delivery","volume":"17","author":"Amjadi","year":"2017","journal-title":"Curr. Gene Ther."},{"issue":"1","key":"10.1016\/j.ejpb.2021.04.026_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2010.11.003","article-title":"Potentials of new nanocarriers for dermal and transdermal drug delivery","volume":"77","author":"Neubert","year":"2011","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2021.04.026_b0105","article-title":"Nanocarriers for transdermal drug delivery","volume":"1","author":"Escobar-Chavez","year":"2012","journal-title":"Res. Rep. Transdermal Drug Delivery"},{"issue":"5","key":"10.1016\/j.ejpb.2021.04.026_b0110","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2174\/1389200218666170222150555","article-title":"Transdermal drug delivery: opportunities and challenges for controlled delivery of therapeutic agents using nanocarriers","volume":"18","author":"Das Kurmi","year":"2017","journal-title":"Curr. Drug Metab."},{"issue":"1","key":"10.1016\/j.ejpb.2021.04.026_b0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2017.10.046","article-title":"Lipid nanocarriers as skin drug delivery systems: properties, mechanisms of skin interactions and medical applications","volume":"535","author":"Sala","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"11","key":"10.1016\/j.ejpb.2021.04.026_b0120","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1166\/jbn.2014.1857","article-title":"Colloidal soft nanocarrier for transdermal delivery of dopamine agonist: ex vivo and in vivo evaluation","volume":"10","author":"Patel","year":"2014","journal-title":"J. Biomed. Nanotechnol."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2021.04.026_b0125","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ijpharm.2013.02.014","article-title":"Comparative in vitro and in vivo evaluation of lipid based nanocarriers of Huperzine A","volume":"446","author":"Patel","year":"2013","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.ejpb.2021.04.026_b0130","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3390\/ma9090761","article-title":"Nonionic microemulsions as solubilizers of hydrophobic drugs: solubilization of paclitaxel","volume":"9","author":"Lo","year":"2016","journal-title":"Materials (Basel)."},{"issue":"12","key":"10.1016\/j.ejpb.2021.04.026_b0135","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/jps.2600841208","article-title":"Transdermal delivery of drugs with differing lipophilicities using azone analogs as dermal penetration enhancers","volume":"84","author":"Phillips","year":"1995","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.ejpb.2021.04.026_b0140","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.2042-7158.1991.tb03511.x","article-title":"Microemulsions as topical drug delivery vehicles: in-vitro transdermal studies of a model hydrophilic drug","volume":"43","author":"Osborne","year":"1991","journal-title":"J. Pharm. Pharmacol."},{"issue":"7","key":"10.1016\/j.ejpb.2021.04.026_b0145","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1007\/s11095-011-0404-y","article-title":"Microemulsion microstructure influences the skin delivery of an hydrophilic drug","volume":"28","author":"Naoui","year":"2011","journal-title":"Pharm. Res."},{"issue":"5","key":"10.1016\/j.ejpb.2021.04.026_b0150","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1080\/10717540802035319","article-title":"Aerosol OT microemulsions as carriers for transdermal delivery of hydrophobic and hydrophilic local anesthetics","volume":"15","author":"Junyaprasert","year":"2008","journal-title":"Drug Deliv."},{"issue":"2","key":"10.1016\/j.ejpb.2021.04.026_b0155","doi-asserted-by":"crossref","first-page":"564","DOI":"10.3109\/10717544.2014.935532","article-title":"Permeation enhancer strategies in transdermal drug delivery","volume":"23","author":"Marwah","year":"2016","journal-title":"Drug Deliv."},{"issue":"1","key":"10.1016\/j.ejpb.2021.04.026_b0160","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/pharmaceutics6010052","article-title":"Overcoming the cutaneous barrier with microemulsions","volume":"6","author":"Lopes","year":"2014","journal-title":"Pharmaceutics."},{"issue":"4","key":"10.1016\/j.ejpb.2021.04.026_b0165","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/10837450.2016.1148722","article-title":"Progress in the use of microemulsions for transdermal and dermal drug delivery","volume":"22","author":"Ita","year":"2017","journal-title":"Pharm. Dev. Technol."},{"issue":"6","key":"10.1016\/j.ejpb.2021.04.026_b0170","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v24.i6.20","article-title":"Microemulsions: applications in transdermal and dermal delivery","volume":"24","author":"Date","year":"2007","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"issue":"8","key":"10.1016\/j.ejpb.2021.04.026_b0175","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/mds.20054","article-title":"Transdermal apomorphine permeation from microemulsions: a new treatment in Parkinson's disease","volume":"19","author":"Priano","year":"2004","journal-title":"Mov. Disord."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2021.04.026_b0180","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ijpharm.2008.06.028","article-title":"Development of SLNs from natural lipids: application to topical delivery of tretinoin","volume":"363","author":"Mandawgade","year":"2008","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.ejpb.2021.04.026_b0185","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/00914037.2019.1706507","article-title":"Enhanced transdermal permeation of rasagiline mesylate nanoparticles: design, optimization, and effect of binary combinations of solvent systems across biological membrane","volume":"70","author":"Bali","year":"2021","journal-title":"Int. J. Polym. Mater. Polym. Biomater."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2021.04.026_b0190","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0378-5173(01)00634-2","article-title":"Transdermal delivery of naloxone: effect of water, propylene glycol, ethanol and their binary combinations on permeation through rat skin","volume":"219","author":"Panchagnula","year":"2001","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.ejpb.2021.04.026_b0195","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/03639040600814676","article-title":"Formulation and evaluation of Nanostructured Lipid Carrier (NLC)-based gel of Valdecoxib","volume":"32","author":"Joshi","year":"2006","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"6","key":"10.1016\/j.ejpb.2021.04.026_b0200","first-page":"577","article-title":"Effect of preferential cyclooxygenase-2 (COX-2) inhibitor against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced striatal lesions in rats: behavioral, biochemical and histological evidences","volume":"48","author":"Gupta","year":"2010","journal-title":"Indian J. Exp. Biol."},{"issue":"1\u20132","key":"10.1016\/j.ejpb.2021.04.026_b0205","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijpharm.2012.08.037","article-title":"Comparison of the cutaneous iontophoretic delivery of rasagiline and selegiline across porcine and human skin in vitro","volume":"438","author":"Kalaria","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2021.04.026_b0210","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ejpb.2018.02.031","article-title":"Simultaneous controlled iontophoretic delivery of pramipexole and rasagiline in vitro and in vivo: transdermal polypharmacy to treat Parkinson's disease","volume":"127","author":"Kalaria","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2021.04.026_b0215","article-title":"Pharmacokinetics, pharmacodynamics, and safety of a single escalating dose and repeated doses of rasagiline transdermal patch in healthy Chinese subjects","author":"Wang","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"2","key":"10.1016\/j.ejpb.2021.04.026_b0220","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s40261-017-0588-y","article-title":"Pharmacokinetics, pharmacodynamics, and safety of rasagiline transdermal patch: a preliminary study in healthy Chinese subjects","volume":"38","author":"Zhou","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"10.1016\/j.ejpb.2021.04.026_b0225","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.apsb.2015.07.003","article-title":"Insoluble drug delivery strategies: Review of recent advances and business prospects","volume":"5","author":"Kalepu","year":"2015","journal-title":"Acta Pharmaceutica Sinica B."},{"key":"10.1016\/j.ejpb.2021.04.026_b0230","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/j.biopha.2018.10.021","article-title":"Biomedical applications of microemulsion through dermal and transdermal route","volume":"108","author":"Shukla","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"4","key":"10.1016\/j.ejpb.2021.04.026_b0235","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3390\/pharmaceutics9040037","article-title":"Topical nano and microemulsions for skin delivery","volume":"9","author":"Nastiti","year":"2017","journal-title":"Pharmaceutics."},{"issue":"1","key":"10.1016\/j.ejpb.2021.04.026_b0240","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1208\/s12249-017-0811-4","article-title":"Design and development of repaglinide microemulsion gel for transdermal delivery","volume":"19","author":"Shinde","year":"2018","journal-title":"AAPS PharmSciTech."},{"key":"10.1016\/j.ejpb.2021.04.026_b0245","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejps.2017.07.014","article-title":"Ex vivo and in vivo evaluation of microemulsion based transdermal delivery of E. coli specific T4 bacteriophage: a rationale approach to treat bacterial infection","volume":"107","author":"Rastogi","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2021.04.026_b0250","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.colsurfb.2015.11.064","article-title":"Transport efficiency in transdermal drug delivery: what is the role of fluid microstructure?","volume":"139","author":"Liuzzi","year":"2016","journal-title":"Colloids Surf., B"},{"issue":"3","key":"10.1016\/j.ejpb.2021.04.026_b0255","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2174\/157016381103141128113034","article-title":"Microemulsions based transdermal drug delivery systems","volume":"11","author":"Vadlamudi","year":"2014","journal-title":"Curr. Drug Discov. Technol."},{"issue":"8","key":"10.1016\/j.ejpb.2021.04.026_b0260","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1208\/s12249-018-1196-8","article-title":"Skin penetration and permeation properties of Transcutol\u00ae-neat or diluted mixtures","volume":"19","author":"Osborne","year":"2018","journal-title":"AAPS PharmSciTech."},{"issue":"1","key":"10.1016\/j.ejpb.2021.04.026_b0265","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1080\/10717544.2018.1523256","article-title":"Effects of solvents and penetration enhancers on transdermal delivery of thymoquinone: permeability and skin deposition study","volume":"25","author":"Haq","year":"2018","journal-title":"Drug Deliv."},{"issue":"3","key":"10.1016\/j.ejpb.2021.04.026_b0270","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2174\/1567201814666170503142707","article-title":"Impact of surfactants on skin penetration of dexpanthenol","volume":"15","author":"Laffleur","year":"2018","journal-title":"Curr. Drug Deliv."},{"issue":"3","key":"10.1016\/j.ejpb.2021.04.026_b0275","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bcpt.13131","article-title":"Pharmacokinetics and safety of single and multiple doses of rasagiline in healthy Japanese and caucasian subjects","volume":"124","author":"Elgart","year":"2019","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"51","key":"10.1016\/j.ejpb.2021.04.026_b0280","doi-asserted-by":"crossref","first-page":"42026","DOI":"10.1074\/jbc.M508628200","article-title":"Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication","volume":"280","author":"Panov","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.ejpb.2021.04.026_b0285","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.pbb.2011.09.002","article-title":"Acetyl-L-carnitine and alpha-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson's disease therapy","volume":"100","author":"Zaitone","year":"2012","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"6","key":"10.1016\/j.ejpb.2021.04.026_b0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020677","article-title":"Edaravone guards dopamine neurons in a rotenone model for Parkinson's disease","volume":"6","author":"Xiong","year":"2011","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1016\/j.ejpb.2021.04.026_b0295","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1474-4422(03)00307-7","article-title":"Gastrointestinal dysfunction in Parkinson's disease","volume":"2","author":"Pfeiffer","year":"2003","journal-title":"Lancet Neurol."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121001247?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641121001247?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:43:26Z","timestamp":1760546606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641121001247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":59,"alternative-id":["S0939641121001247"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.04.026","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Microemulsion-based gel for the transdermal delivery of rasagiline mesylate: In vitro and in vivo assessment for Parkinson\u2019s therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2021.04.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}